The aim of this study was to determine, in pregnancies complicated by preterm premature rupture of membranes (PPROM), hypertension, intrauterine growth restriction, multi-fetal gestations and pregnancies 23-26 weeks and ≥34 weeks' gestation, whether antenatal corticosteroids benefit the fetus. Literature review using PubMed, Web of Science, Clinical trials.gov, Cochrane Database of Systematic Reviews (1990Reviews ( -2015. Search terms linked special circumstances with corticosteroids. Randomized clinical trials, retrospective and prospective cohort studies, and case control studies were reviewed. In all, 468 abstracts were identified and 84 added from selected article bibliographies; of these, 503 abstracts were excluded, leaving 49 articles as the basis of review. The literature supports corticosteroids for PPROM up to 32-34 weeks without chorioamnionitis. Antenatal corticosteroids are beneficial for preterm infants of women with HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome/severe preeclampsia. Postpartum corticosteroid treatment of HELLP patients results in more rapid correction of liver enzymes, platelet counts, and urinary output, which can reduce maternal morbidity. Corticosteroids in twin pregnancies decrease respiratory distress syndrome but the effect is less than in singleton pregnancies. Corticosteroid effects on intrauterine growth restriction pregnancies are conflicting and steroid use should be individualized. Corticosteroid use for 23-26 weeks reduces neonatal mortality but not morbidity.
Introduction
Since the work of Liggins & Howie (1) , there have been numerous scientific articles about the use of maternal corticosteroids to reduce neonatal respiratory distress syndrome (RDS). Such steroid treatment has been recommended by the National Institutes of Health, the American Congress of Obstetrics and Gynecology (ACOG), and the American Academy of Pediatrics (AAP) as well as other groups for women at risk for preterm delivery (>26-34 weeks) (2) . Corticosteroids in at-risk women significantly reduce neonatal morbidity/mortality and result in substantial health cost savings (2) . Questions remain about the method of action of corticosteroids, the best preparation, and dosing/timing, but generally when faced with a preterm delivery, the use of corticosteroids to induce fetal lung maturity is indicated. Corticosteroid administration (one to two courses) appears safe in both short-and long-term analysis for the mother and fetus (3) .
There are patients with special circumstances where antenatal corticosteroids have not been fully evaluated. Women with preterm premature rupture of the membranes (PPROM), hypertension, intrauterine growth restriction (IUGR), near-term delivery (34-38 weeks), multi-fetal pregnancies, and the very preterm (23-26 weeks' gestation) are areas deserving research. For example, HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets -a severe variant of preeclampsia) has been studied but outcomes are conflicted by medication issues (various drugs/dosages/routes and timing of administration), the patient's illness severity, and different outcomes evaluated.
The purpose of our study was to undertake a comprehensive literature review in each of these areas and formulate, when possible, recommendations for clinicians based on the evidence.
Material and methods
The literature review used various search engines (PubMed, Web of Science, clinical trials.gov, Cochrane Database of Systematic Reviews) and assessed the years 1990-2015. The search combined the special uses of corticosteroids in pregnancies with PPROM, HELLP syndrome, severe preeclampsia, and IUGR, and their use at 23-26 and ≥34 weeks' gestations. Search terms used for corticosteroids were adrenal cortex hormones, therapeutic use OR "corticosteroids" OR "betamethasone" OR "dexamethasone" OR "hydrocortisone" AND "rupture of the fetal membranes, premature rupture" OR "PPROM". Corticosteroids AND "HELLP syndrome" OR "HELLP" OR "preeclampsia" OR "severe preeclampsia" were used.
Corticosteroids AND "fetal growth restriction" OR "IUGR" or "SGA" (small for gestational age) were assessed, as were Corticosteroids AND "transient tachypnea of the newborn/drug therapy" OR "respiratory distress syndrome, newborn/prevention and control". All searches were repeated using the same terms for multiples "twins" OR "triplets" OR "quadruplets" or "quintuplets". Studies included were randomized controlled trials, Cochrane reports, nonrandomized controlled trials, prospective and retrospective cohort studies, and casecontrol studies. Case reports, reviews, case series, discussions, editorials, non-human studies, articles without control groups, and steroid treatment for other reasons were excluded. All abstracts were read by two of the authors (J.C.M. and E.F.M.). Any disagreements between reviewers were resolved by in-depth discussion. The full articles of selected abstracts were reviewed by these two authors. Finally, bibliographies of review articles and published meta-analysis on the subject were reviewed for additional relevant articles. This study was submitted to the Institutional Review Board. Because this study is a literature review of previously published articles it does not meet the definition of research involving human subjects and is therefore not subject to Institutional Review Board oversight. This review was registered with PROPERO (CRD42016039023).
The assigned levels of evidence for the references used in this review come from the Australian National Health and Medical Research Council (NHMRC) classification of levels of evidence (Table 1) .
Statistical analyses
We calculated effect estimates expressed as relative risk and 95% confidence intervals for each study. For outcomes of interest, the calculated effect estimates were pooled to obtain the overall effect. Heterogeneity between studies was assessed using the Q-statistic and Higgins' I we pooled data using a random effects model. For outcomes where at least eight studies were available for the meta-analysis, publication bias was evaluated by funnel plot and Egger's asymmetrical test. If potential publication bias was detected, we adjusted our meta-analysis results using a nonparametric trim-and-fill approach. Finally, to evaluate the constancy of our results, sensitivity analysis was conducted using a leave-one-out method. All data analyses were performed using the R package "metafor".
Results
There were 468 abstracts identified from the literature search. Of these, 420 were excluded (case reports, animals studies, review articles, descriptive studies without a control group, etc.) and 84 were added from a review of the bibliographies. After exclusions, 49 papers were left, forming the basis of this review (Figure 1 ).
PPROM and corticosteroid administration
We identified 17 controlled trials in our comprehensive literature review of pregnancies complicated by PPROM in which women who received corticosteroids were compared with women who did not (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Combined data from those trials involving >1900 women with PPROM confirmed that corticosteroids reduce the perinatal risks of intraventricular hemorrhage (IVH), grade III and IV [relative risk (RR) = 0.49, 95% confidence interval (CI) 0.25-0.96], IVH grade I-IV (RR = 0.52, 95% CI 0.37-0.72), and RDS (RR = 0.81, 95% CI 0.67-0.98) (Figure 2) . No difference was observed between steroid and control groups concerning the risk for necrotizing enterocolitis (NEC), neonatal sepsis, Apgar score <7 at five minutes ( Figure 3 ). Perinatal/neonatal mortality and maternal chorioamnionitis was also similar between steroid and control groups (Figure 4) .
Because of an association between clinical chorioamnionitis and cystic periventricular leukomalacia/cerebral palsy, there has been concern about corticosteroid use in pregnancies complicated by PPROM. None of the patients had signs/symptoms of chorioamnionitis when treatment was iniated and movement toward delivery was not delayed to finish a course of steriods. A meta-analysis of observational studies demonstrated corticosteroids were effective in reducing neonatal morbidity/mortality (IVH -grade III, IV, and periventricular leukomalacia) even if histologic or clinical chorioamnionitis developed after treatment started (23 Added from review of the bibliographies of the read papers. c 11 articles HELLP Syndrome, 2 articles severe preeclampsia. required and infection was noted after steroid treatment. Multiple or repeated courses of steroids were not used in these studies (24) .
Severe preeclampsia/HELLP syndrome and corticosteroid administration
Preeclampsia is a pregnancy complication with severe variants including eclampsia, severe preeclampsia and HELLP syndrome. Corticosteroid treatment of women with eclampsia has not been evaluated. There are few studies in severe preeclampsia, but HELLP syndrome has been more thoroughly studied (25) . Corticosteroids have been used antepartum, intrapartum, and postpartum in women with HELLP syndrome, usually at dosages (10 mg every 12 h) (26) above those employed for fetal lung maturity (25) . In 2010, the Cochrane Database reviewed corticosteroid use for women with HELLP syndrome (26) . They assessed 16 different randomized clinical trials; however, not all of them met the inclusion criteria. Using the references that met the inclusion criteria and our additional studies, resulted in 13 investigations being analyzed (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) . In the report by Fonseca et al. (27) steroid treatment was begun before delivery and continued after birth. In five investigations, pregnant women were only treated antepartum and in the remainder, treatment was only postpartum. Isler et al. (28) compared dexamethasone with betamethasone (29) (30) (31) (32) (33) . Three trials involving 278 women did not detect any difference between the treatment groups (death or severe maternal morbidity) (27, 29, 32 (30,32). These two trials found no statistically significant differences between groups in composite perinatal morbidity following corticosteroid treatment. In summary, antenatal treatment with corticosteroids compared with a control group did not improve either maternal or infant outcomes. Nevertheless, patients with HELLP syndrome, if preterm, will show the same positive results (less neonatal RDS etc.) as mothers without HELLP syndrome.
IVH Grade III/IV (a) (b) RDS
The remainder of the studies utilized only women treated postpartum and measured the effect of corticosteroids on platelets, urinary output, and liver enzyme recovery (33) (34) (35) (36) (37) . In only one reference, dexamethasone appeared to have a superior effect compared with betamethasone on platelet count (RR = 6.02, 95% CI 1.71-10.33) regardless of whether treatment was antepartum or postpartum (28) . Aspartate transaminase (AST) and alanine transaminase (ALT) recovered more rapidly in two trials of 
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Nelson 1985 Pattinson 1999 Qublan 2001 Yang 2004 (33, 37, 38) . These changes involve laboratory tests but clinicians may find benefit in a reduction of maternal morbidity when the platelets rise while lever/renal involvement more rapidly returns to normal. There has been controversy about the benefit of antepartum corticosteroid therapy at various platelet counts between 50 000 and 150 000 particularly in pregnancies with a platelet nadir of <50 000. A triple-blind randomized controlled trial by the COHELLP Study Group is comparing dexamethasone with a placebo in women with a platelet nadir <50 000 and may offer a definitive answer (39) . Two investigations evaluated the use of corticosteroids in severe preeclampsia. Amorim et al. (40) noted the corticosteroid group had significantly less neonatal RDS compared with the placebo group. The maternal complications of severe hypertension, acute renal failure, acute pulmonary edema, infection, and maternal death were similar between corticosteroid and placebo groups. In a study by Barrilleaux et al. (41) there was an increased risk for gestational diabetes in the corticosteroid group, whereas the morbidities of severe preeclampsia were not reduced compared with placebo treatment. Again, corticosteroid benefit to preterm fetuses should be expected in such women, and there is therefore no reason to withhold therapy.
Twin pregnancy and corticosteroid administration
The worldwide incidence of twin pregnancies has increased significantly over the past few decades mainly because of the widespread use of assisted reproductive technologies (ART) and increasing maternal age at conception. There is significant risk of delivering preterm associated with multiple gestations, with nearly 60% of twins being born prematurely (<37 weeks) and 12-14.5% before 34 weeks. The higher preterm delivery rate is associated with an increased risk of neonatal morbidity/mortality. Some have suggested that corticosteroids are ineffective in multiple gestations because the larger volume of distribution has a dilational effect on fetal drug concentration. Others, however, suggest a similar volume of distribution between singleton and twin pregnancies. Gyamfi et al. (42) found that maternal and umbilical cord serum betamethasone concentrations at delivery were similar in singleton and twin gestations, suggesting that any decrease in effectiveness is not due to inadequate fetal drug levels. The most likely reason that twins have not demonstrated improvement following steroids is probably related to the small sample size of the randomized controlled trials, which gives them insufficient power to confirm a difference. A large population-based study examined RDS in singleton, twin, and triplet gestations exposed to corticosteroids with delivery at 24-32 weeks (42) ( Figure 5 ). Corticosteroids reduced the risk of RDS in both twins and triplets but the benefit was less than with singletons. The study by Quist-Therson et al. (43) enrolled 946 multiple gestations, 396 treated with corticosteroids vs. 550 not treated, and showed a trend toward reduction of RDS in the multiple gestations, although this was not statistically significant. In a retrospective cohort study of 117 twin pregnancies, it was found that corticosteroids, either as a single or multiple courses, did not reduce RDS in twins born between 24 and 34 weeks (44) . However, the study was limited by the small number of twins and the fact that the time interval from corticosteroid administration to delivery was not evaluated. Kuk et al. (45) undertook a retrospective cohort study of twins (24-34 weeks) receiving maternal treatment with corticosteroids. The women were grouped based on the time from first steroid dose and delivery (less than 2 days, 2-7 days, and more than 7 days) and were compared with a control group. As expected, RDS in the group with a corticosteroid-todelivery interval of less than 2 days or more than 7 days was not significantly different from the control group. RDS occurred significantly less frequently when the corticosteroid-to-delivery interval was between 2-7 days [odds ratio (OR) = 0.419, 95% CI 0.181-0.968] (45). These data suggest that the corticosteroid effect decreases after 7 days and a rescue course of corticosteroids may be indicated in multiple pregnancies remaining at risk. We identified three additional controlled trials in our comprehensive literature review of pregnancies complicated by a twin pregnancy in which women who received corticosteroids were compared with women who did not (20, 46, 47) . Combined data from these trials involving more than 500 women with twin pregnancies revealed no difference in risk for RDS between the steroid group and the control group (RR = 0.66, 95% CI 0.37-1.19) ( Figure 5 ).
Intrauterine growth restriction and corticosteroid administration
There are no randomized trials on the benefits and risks of corticosteroid treatment in IUGR. One large study of IUGR fetuses from the Vermont Oxford Network database demonstrated that corticosteroid administration was associated with significantly lower risks of RDS, overall IVH (grade I-IV), severe IVH (grade III and IV), and perinatal death; however, the incidence of NEC was not (51) evaluated the effect of corticosteroids in preterm IUGR neonates delivered by cesarean because of fetal distress before labor at 26-32 weeks. Fetuses treated with corticosteroids more than 24 h but less than 7 days before birth, were matched with infants whose mothers were not treated with steroids. The main outcome was survival without disability or handicap at a corrected age of 2 years. Survival without disability was more frequent in the corticosteroid group (OR = 3.2, 95% CI 1.1-11.2). The long-term follow up at school age revealed a negative effect of steroids on physical growth (OR = 5.1, 95% CI 1.4-23.8) but no differences in behavior. It was concluded that benefits from corticosteroids for early preterm, IUGR fetuses outweighed possible adverse effects (51) . We identified these other controlled trials in our comprehensive literature review of pregnancies complicated by IUGR in which women who received corticosteroids were compared with women who did not (20, (52) (53) (54) . Combined data from these four trials involving almost 700 women with growth-restricted fetuses revealed no difference between the steroid group and the control group as regards the risk for RDS (RR = 0.89. 95% CI 0.74-1.07), IVH overall (RR = 1.28, 95% CI 0.78-2.11), IVH grade III and IV (RR = 0.38, 95% CI 0.13-1. (Figure 6a-c) .
Pregnancies at <23-26 weeks' gestation and corticosteroid administration
A systematic review by Onland et al. (55) assessed the effects of corticosteroids in pregnancies prior to 26 weeks. The nine trials reported included pregnancies greater than and less than 26 weeks; however, none specifically reported outcomes for pregnancies <26 weeks. The overall conclusion was that there were neither benefits nor risks of antenatal corticosteroid treatment below 26 weeks but the authors stated that "the numbers were very small". In the seminal work by Liggins et al. (1), the investigators found a small number of women (n = 49) who were treated with betamethasone vs. placebo at 23-26 weeks. There was no difference between the groups in perinatal/neonatal deaths and no difference in the percentage of infants with RDS or IVH between treatment and control groups. A recent systematic review and meta-analysis (56) regarding this subject assessed the effectiveness of antenatal corticosteroids (vs. placebo) at 23-24 weeks' gestation. Seventeen observational studies were included, the primary outcome being newborn mortality to discharge (n = 3626). Mortality from birth to discharge was reduced by 52% in treatment group (OR = 0.45, 95% CI 0.36-0.56). Therefore, although it is possible that at gestational ages 23-26 weeks, steroids may not work effectively on lung tissue to prevent RDS, a reduction in overall neonatal mortality is a significant benefit.
Pregnancies at ≥34 weeks' gestation and corticosteroid administration
Three controlled trials involving pregnancies delivered beyond 34 weeks compared women who received corticosteroids with those who did not (57) (58) (59) . The combined data involved over 12 000 women with deliveries beyond 34 weeks. The risk for RDS was reduced by steroid treatment (RR = 0.38, 95% CI 0.14-1.00) (Figure 7 ). Women at 34-36 weeks' gestation were randomized to receive a single dose of betamethasone vs. no treatment in one study (57) . The corticosteroid group had significantly better Apgar scores, required less resuscitation at birth, and had fewer neonates with RDS. Antenatal corticosteroids in pregnancies >34 weeks was assessed in an observational cohort study from Sweden (58) . The corticosteroid-treated neonates had less RDS but slightly smaller neonatal head size, and lower Apgar scores compared with the non-treated neonates. In another study, fetuses with mature fetal lungs were compared with those with immature fetal lungs treated with corticosteroids and fetuses with immature lungs managed expectantly (60) . Newborns with mature fetal lungs and those with immature fetal pulmonary indices managed expectantly had less RDS than the fetuses with immature lungs treated with corticosteroids.
Women undergoing cesarean delivery at ≥37 weeks who received antenatal corticosteroids had fewer neonates admitted to the special care unit for respiratory distress compared with a control group not treated with steroids (61) . In two investigations, pregnant women receiving corticosteroids prior to 34 weeks but delivering between 34 and 37 weeks did not have reduced neonatal respiratory morbidity compared with the group not treated with corticosteroids (62, 63) . Unfortunately, the newborn findings were not adjusted for the time between steroid treatment and delivery (in some cases up to 9 weeks). Therefore, lack of a positive effect may have been due to the birth occurring after the steroid effect had subsided. More recently, the National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network published results from their randomized trial at 17 tertiary centers over a four and a half year period where women at 34 0/7 to 36 6/7 completed weeks' gestation with singleton pregnancies were randomized to receive steroid or placebo (betamethasone, n = 1429; placebo, n = 1402) (64) . There was a reduction in severe respiratory morbidity [RDS, transient tachypnea of the newborn (TTN), surfactant use, bronchopulmonary dysplasia (BPD)] when steroid treatment was compared with placebo (p = 0.023) The incidence of chorioamnionitis which occurred after steroid treatment was reduced by almost half compared with the placebo group, but the difference was not statistically significant (p = 0.08). Neonatal hypoglycemia (glucose <40 mg/dL) was more common (24% vs. 15%) among betamethasone-treated mothers (p = 0.001). All of these findings occurred at a similar gestational age of delivery -36.1 weeks in both groups (p = 0.517).
Multiple courses of corticosteroids
The majority of studies worldwide have dealt with a single dose of corticosteroids to reduce the incidence of neonatal RDS (65) . However, since 50% of women remain pregnant for seven to 14 days after steroid treatment, the administration of repeated courses of steroids became common practice in the 1980s and 1990s (66) . Unfortunately, multiple courses of steroids revealed adverse short-term/long-term neonatal effects; therefore, the practice of three or more courses of corticosteroids is not recommended (67) . However, studies have shown neonatal benefit with a "rescue course" of corticosteroids (limited to two total courses of corticosteroids) when the risk of preterm delivery continued more than 7 days after the initial dose and this has become a standard procedure. For example, Garite et al. (68) published a randomized double-blind, placebo controlled, multi-center trial using a rescue course of steriods. In that study, 437 patients were randomized to receive either a second (rescue) course of steroids (n = 223) or placebo (n = 214) as their treatment. There was a significant reduction (with rescue steroids) in composite neonatal morbidity (43.9% vs. 63.6%) as well as a significant decrease in RDS, ventilator support, and surfactant use (68) . The authors concluded that the administration of a second or rescue course of corticosteroids before 33 weeks improved neonatal outcome without increased risk (68) . Likewise, a Cochrane Review by McKinlay et al. (69) reviewed the issue of rescue corticosteroids and noted a reduced risk of RDS (RR = 0.83, 95% CI 0.75-0.91) with a two-year follow up indicating no evidence of significant harm. There was a slight decrement in birthweight in these trials when the baby was exposed to one or both courses of steroids. Lastly, McEvoy et al. (70) published a randomized clinical trial regarding rescue corticosteroid treatment. They noticed no significant difference in birthweight or head circumference compared with the placebo group, but showed increased respiratory compliance (p = 0.04) and less neonatal oxygen requirement when compared with women treated with placebo. When patients delivering ≤34 weeks were separately stratified, RDS was also significantly reduced among treated women (70) . In summary, a second course of steroids (rescue treatment) should be considered in women seven or more days after their first course of steroids if they remain at risk for preterm birth. Weekly courses or three or more courses of corticosteroids are not recommended.
Adverse effects of corticosteroid treatment
Corticosteroid treatment has been associated in some studies with decreased birthweight. Bloom et al. (50) noted a small decrement of birthweight (63-161 g) between 26 and 34 weeks' gestation compared with untreated infants. Banks et al. (71) found a similar birthweight reduction in steroid-treated infants if they received more than one course of corticosteroids (72) . In addition, since corticosteroids caused an impaired glucose tolerance in treated women, some investigators have noted an elevated risk of neonatal hypoglycemia (blood glucose <45 g/dL) (60) . Likewise, when steroids are administered antenatally, there has been a noted decrease in fetal heart rate variability, body movement, and fetal breathing motions (73) (74) (75) .
There have also been several studies assessing long-term neonatal effects of corticosteroids used to enhance lung maturity. Exposure to a single course of corticosteroids did not reveal any effects on blood pressure, memory, attention span, psychiatric morbidity or health-related quality of life as an adult in extensive follow-up studies of treated infants vs. placebo (76, 77) . In addition, two of the largest multi-center studies have now published their follow-up results on women with repeated courses, which were also quite reassuring (71, 78) . In another long-term follow-up study (median 12.2 years), a single course of antenatal betamethasone did not result in learning difficulty, psychosocial behavior, hyperactivity or emotional symptoms (79) .
While the long-term effects on children treated with corticosteroids to reduce RDS appear to be scant from a physical development and medical history standpoint (10-to 12-year follow up) (3), the effects (particularly with repeated steroid courses) on the weight of several organs (liver, lungs, heart, thymus, kidneys, placenta, etc.) as well as the reduced axonal myelination in animal models must be considered. Although steroid administration does not cause an increased risk of choroaminiotis and neonatal sepsis in patients with PPROM (23, 24) , the potential effect on fetuses with IUGR are concerning. For example, Bloom et al. (52) revealed significantly lower birthweight at various gestational ages. Schapp et al. (51) noted a negative effect of steroids on physical growth while confirming an increased survival without handicap in steroid-treated infants. These adverse effects may be the result of the pathophysiology behind IUGR, but further investigation in this population is warranted.
In a non-randomized regional cohort of singleton pregnancies followed up to 3 years, it was noted that an increasing number of corticosteroid courses (more than two) was associated with increase rates of aggressive/destructive behavior as well as hyperkinetic children. However, the rate of cerebral palsy was decreased (80) . Likewise, when the number of steroid treatments was two or more, there was an increasing amount of leukomalacia and neurodevelopmental abnormalities (81) . In summary, it appears that there are few deleterious short-term neonatal side effects or long-term adverse effects in children when no more than two steroid courses are given. In contrast, multiple (≥32) courses of corticosteroids given to enhance lung maturity have resulted in adverse effects. Therefore, it is recommended to consider a second (rescue) course of corticosteroids when there is continued risk for early birth (<34 weeks) and 7 days have elapsed since the initial treatment. However, three or more courses of corticosteroids should be avoided.
Conclusions
Hopefully, the comprehensive data analysis presented (summarized below) will help physicians with their choice to treat or not to treat women in these categories with corticosteroids (Table 2) . Research in the area of the fetal effects of such treatment should continue.
Preterm premature rupture of the membranes
The overall evidence supports the administration of corticosteroids in patients with PPROM up to 32-34 weeks in the absence of chorioamnionitis. However, delivery should not be delayed in the setting of clinical chorioamnionitis to allow the administration of antenatal corticosteroids.
Severe preeclampsia/HELLP
Treatment with antenatal corticosteroid in pregnancies complicated by HELLP syndrome or severe preeclampsia vs. controls shows no reduction in fetal or neonatal adverse outcomes. However, preterm infants benefit from maternal steroid treatment to the same degree as control HELLP, hemolysis, elevated liver enzymes, and low platelets; IVH, intraventricular hemorrhage; PPROM, preterm premature rupture of the membranes; RCT, randomized controlled trial; RDS, respiratory distress syndrome.
infants without adverse newborn effects. There are significant benefits of postpartum maternal treatment to speed normalization of platelet counts, liver function and urinary output, thus potentially reducing maternal morbidity, without negative consequences in such women.
Multifetal pregnancies
While the number of studied twin gestations is relatively small, there is evidence of a salutary effect of steroids on neonatal RDS (although the effect is less than that observed in singleton pregnancies). It is also more important (than in singletons) that treatment occur within one to seven days before delivery (rather than 10 or 14) to have the maximal effect on RDS.
Intrauterine growth restriction
The effect on corticosteroid administration on IUGR fetuses is conflicting, with large cohort studies revealing significantly lower rates of RDS/IVH and prenatal death than found in small randomized clinical trials, which showed no reduction in neonatal morbidity. Accordingly, steroid use for these patients should be individualized. If a single course of steroid treatment is used, the small decrement in birthweight noted after multiple courses of treatment in such patients appears to be negated. In the largest cohort study there was greater survival and less disability at 2 years of age with steroid treatment. The benefit of maternal steroids in IUGR fetuses outweighs the possible adverse effects.
Pregnancies 23-26 weeks
In this category there is evidence of a reduction in neonatal mortality with steroid administration. However, there is not enough data to make a recommendation regarding a reduction in neonatal morbidity in steroid-exposed newborns. Overall, there were no negative neonatal effects among these studies.
Pregnancies >34 weeks
The evidence shows that there are fewer infants with serious respiratory morbidity after maternal steroid treatment but there are no long-term outcome studies in this group of patients.
